Cystic fibrosis treatment methods
View Patent ↗The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
1. A compound having the structure
wherein
R 1 is —OH or an ester;
R 2 is —OH or an ether;
R 3 is —OH, ═O, a halogen, an ester or ═CH 2 ; and
R 4 is an optionally substituted amine, an amide, an N-linked amino acid, ═NOH or —NHOH.
2. The compound of claim 1 having the structure
3. The compound of claim 2 wherein
R 1 is —OH;
R 2 is —OH;
R 3 is —OH, ═O, —F, —Br, —O—C(O)—CH 3 or —O—C(O)—CH 2 CH 3 ; and
R 4 is —NH 2 , —NH—C(O)CH 3 , ═NOH, —NHCH 3 , —N(CH 3 ) 2 , —NH—C 2 H 5 or —NHOH.
4. The compound of claim 3 having the structure
5. The compound of claim 4 wherein the compound is 3β,7β-dihydroxy-16α-fluoro-17β-aminoandrostane.
6. The compound of claim 1 having the structure
7. The compound of claim 6 wherein
R 1 is —OH;
R 2 is —OH;
R 3 is —OH, ═O, —F, —Br, —O—C(O)—CH 3 or —O—C(O)—CH 2 CH 3 ; and
R 4 is —NH 2 , —NH—C(O)CH 3 , ═NOH, —NHCH 3 , —N(CH 3 ) 2 , —NH—C 2 H 5 or —NHOH.
8. The compound of claim 7 having the structure
9. The compound of claim 8 wherein the compound is 3β,7β-dihydroxy-16-oxo-17β-aminoandrost-5-ene.
10. A pharmaceutical formulation comprising one or more excipients and a compound having the structure
wherein
R 1 is —OH or an ester;
R 2 is —OH or an ether;
R 3 is —OH, ═O, a halogen, an ester or ═CH 2 ; and
R 4 is an optionally substituted amine, an amide, an N-linked amino acid, ═NOH or —NHOH.
11. The pharmaceutical formulation of claim 10 wherein the compound has the structure
12. The pharmaceutical formulation of claim 11 wherein
R 1 is —OH;
R 2 is —OH;
R 3 is —OH, ═O, —F, —Br, —O—C(O)—CH 3 or —O—C(O)—CH 2 CH 3 ; and
R 4 is —NH 2 , —NH—C(O)CH 3 , ═NOH, —NHCH 3 , —N(CH 3 ) 2 , —NH—C 2 H 5 or —NHOH.
13. The pharmaceutical formulation of claim 12 wherein the compound is 3β,7β-dihydroxy-16α-fluoro-17β-aminoandrostane or 3β,7β-dihydroxy-16-oxo-17β-aminoandrost-5-ene.